News & Updates

Show Multimedia Only

Metformin, SGLT2is confer protection against dementia

28 Aug 2024

Among various glucose-lowering medications, metformin and sodium glucose co-transporter-2 inhibitors (SGLT2is) are associated with a reduced risk of dementia, as shown in the results of a meta-analysis.

Metformin, SGLT2is confer protection against dementia

28 Aug 2024

Gestational diabetes linked to altered gut microbiome and larger head circumference in male offspring

28 Aug 2024 by

Gestational diabetes mellitus (GDM) not only disrupts the gut microbiome of mothers and their infants, but is also linked to increased head circumference in male offspring, researchers from the Chinese University of Hong Kong (CUHK) have shown.

Gestational diabetes linked to altered gut microbiome and larger head circumference in male offspring

28 Aug 2024

Frontline ATRA-ATO regimen improves EFS in high-risk APL

28 Aug 2024 by

The addition of arsenic trioxide (ATO) to all-trans retinoic acid (ATRA) with idarubicin significantly improves event-free survival (EFS) compared with ATRA plus chemotherapy (CHT) in the first-line setting for patients with newly diagnosed, high-risk acute promyelocytic leukaemia (APL), according to the APOLLO trial presented at EHA 2024.

Frontline ATRA-ATO regimen improves EFS in high-risk APL

28 Aug 2024

Clinical role of oral bempedoic acid in LDL-C management

28 Aug 2024 by

LDL-cholesterol (LDL-C) reduction is the key to preventing and treating atherosclerotic cardiovascular disease (ASCVD). Recent guidelines advocate aggressive LDL-C lowering in individuals at high or very high cardiovascular (CV) risk. At the Advances in Medicine 2024 conference, Dr Chu-Pak Lau, Specialist in Cardiology, discussed the clinical role of non-statin lipid-lowering therapies (LLTs), including oral bempedoic acid as a single agent or in fixed-dose combination (FDC) with ezetimibe, in patients who have failed to achieve guideline-recommended LDL-C targets or have statin intolerance.

Clinical role of oral bempedoic acid in LDL-C management

28 Aug 2024

GLP-1 RAs offer CV benefits in T2DM

28 Aug 2024 by

Cardiovascular (CV) benefits of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) support their use in type 2 diabetes mellitus (T2DM). At a Novo Nordisk–sponsored lecture during the 6^th Annual Meeting of Endocrinology, Diabetes and Metabolism Hong Kong (EDM HK), Dr Julie Lovshin of the Division of Endocrinology and Metabolism, University of Toronto, Canada, reviewed clinical trials and real-world evidence on CV benefits provided by GLP-1 RAs, such as semaglutide, which led to guideline recommendations on their use in T2DM. Safety concerns related to GLP-1 RAs were also addressed.

GLP-1 RAs offer CV benefits in T2DM

28 Aug 2024

[Infographics] Don’t stop at HF: Screen for ATTR-CM

28 Aug 2024

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure (HF), affecting 1 in 10 patients with preserved left ventricular ejection fraction. Read this infographic to learn how to screen for ATTR-CM in HF patients and understand the survival benefits of early tafamidis treatment.

[Infographics] Don’t stop at HF: Screen for ATTR-CM

28 Aug 2024

Use of a C5 inhibitor in a patient with AOSD complicated by atypical haemolytic uraemic syndrome

28 Aug 2024 by

A 42-year-old male was hospitalized with a 2-week history of persistent fever, generalized maculopapular rash, and right cervical lymphadenopathy. His medical history and family history were unremarkable.

Use of a C5 inhibitor in a patient with AOSD complicated by atypical haemolytic uraemic syndrome

28 Aug 2024

Corticosteroid elimination with anti–IL-5 antibody in two patients with idiopathic HES

28 Aug 2024 by

A 45-year-old male presented with generalized urticaria in September 2020. He had no past history of allergies, but had transient autoimmune thyroiditis in 2018, which subsequently resolved.

Corticosteroid elimination with anti–IL-5 antibody in two patients with idiopathic HES

28 Aug 2024

Addressing hyperphosphataemia with a polymer-based phosphate binder in a patient with ESRD

28 Aug 2024 by

A 55-year-old male with end-stage renal disease (ESRD) started peritoneal dialysis (PD) in January 2020, with a regimen of nocturnal automated PD with 2 L of 1.5 percent dextrose six shifts per night and 2 L of 7.5 percent icodextrin during the day.

Addressing hyperphosphataemia with a polymer-based phosphate binder in a patient with ESRD

28 Aug 2024

Transthyretin amyloid cardiomyopathy: Tips for early diagnosis and treatment updates

28 Aug 2024

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal condition that predominantly affects older adults. The prognosis is poor, with a median overall survival (OS) of 3–5 years. The condition is often underrecognized or misdiagnosed due to low disease awareness and fragmented knowledge among healthcare professionals across specialties. This article provides practical advice for early diagnosis and treatment, with a focus on 5-year OS data from the ATTR-ACT trial of tafamidis and key recommendations from the 2023 American College of Cardiology (ACC) guidelines.

Transthyretin amyloid cardiomyopathy: Tips for early diagnosis and treatment updates

28 Aug 2024

News & Updates

Filter by Specialty:

Specialty:

Metformin, SGLT2is confer protection against dementia

Metformin, SGLT2is confer protection against dementia

Gestational diabetes linked to altered gut microbiome and larger head circumference in male offspring

Gestational diabetes linked to altered gut microbiome and larger head circumference in male offspring

Frontline ATRA-ATO regimen improves EFS in high-risk APL

Frontline ATRA-ATO regimen improves EFS in high-risk APL

Clinical role of oral bempedoic acid in LDL-C management

Clinical role of oral bempedoic acid in LDL-C management

GLP-1 RAs offer CV benefits in T2DM

GLP-1 RAs offer CV benefits in T2DM

[Infographics] Don’t stop at HF: Screen for ATTR-CM

[Infographics] Don’t stop at HF: Screen for ATTR-CM

Use of a C5 inhibitor in a patient with AOSD complicated by atypical haemolytic uraemic syndrome

Use of a C5 inhibitor in a patient with AOSD complicated by atypical haemolytic uraemic syndrome

Corticosteroid elimination with anti–IL-5 antibody in two patients with idiopathic HES

Corticosteroid elimination with anti–IL-5 antibody in two patients with idiopathic HES

Addressing hyperphosphataemia with a polymer-based phosphate binder in a patient with ESRD

Addressing hyperphosphataemia with a polymer-based phosphate binder in a patient with ESRD

Transthyretin amyloid cardiomyopathy: Tips for early diagnosis and treatment updates

Transthyretin amyloid cardiomyopathy: Tips for early diagnosis and treatment updates